RSS-Feed abonnieren
DOI: 10.1055/s-0029-1245849
© Georg Thieme Verlag KG Stuttgart · New York
Minimale Resterkrankung beim Magenkarzinom – eine Übersicht
Minimal Residual Disease (MRD) in Gastric Carcinoma – an OverviewPublikationsverlauf
Manuskript eingetroffen: 21.8.2010
Manuskript akzeptiert: 19.10.2010
Publikationsdatum:
04. Februar 2011 (online)

Zusammenfassung
Die Prognose des Magenkarzinoms, insbesondere im fortgeschrittenen Stadium, ist trotz der bedeutenden Entwicklungen der letzten Jahre noch immer als schlecht anzusehen. Die Tatsache, dass auch potenziell kurativ behandelte Patienten ohne nachweisbaren Tumorrest in einem erheblichen Teil der Fälle Metastasen entwickeln und adjuvante Therapien dieses Risiko senken können, weist darauf hin, dass bei diesen Patienten Mikrometastasen und isolierte Tumorzellen („minimal residual disease”, MRD) vorliegen, die mit konventionellen Methoden nicht erfassbar sind und zum Ausgangspunkt für Rezidive werden können. Ein Nachweis der MRD in verschiedenen anatomischen Kompartimenten könnte demnach Bedeutung für eine stärkere Individualisierung der Therapie erlangen. Die Untersuchungsmethodik und die Ergebnisbeurteilung sind jedoch bis heute nicht standardisiert und die vorliegenden Studien daher meist nicht vergleichbar, sodass die MRD-Diagnostik zumindest im europäischen und angloamerikanischen Raum bisher für keines der 4 Kompartimente Lymphknoten, Peritonealflüssigkeit, peripheres Blut und Knochenmark Eingang in die klinische Routine gefunden hat. Die besten Daten für den MRD-Nachweis beim Magenkarzinom liegen für die Peritoneallavage vor. Diese Untersuchung ist an einigen japanischen Zentren bereits etabliert und wird für therapeutische Entscheidungen genutzt (z. B. Indikation zur intraperitonealen Chemotherapie). Der MRD-Nachweis in Lymphknoten wird im Zusammenhang mit dem Sentinel-Lymphknoten-Konzept weiter evaluiert werden und hier vor allem bei Patienten mit frühen Tumorstadien, die normalerweise nicht in multimodalen Konzepten behandelt werden, möglicherweise therapeutische Relevanz erlangen. Für Tumorzellen im peripheren Blut und im Knochenmark zeichnet sich ab, dass diese nur unter bestimmten Voraussetzungen zur Metastasenbildung fähig sind. Zukünftige Untersuchungen werden sich daher neben dem reinen Nachweis von Tumorzellen vor allem auf deren molekulare Charakterisierung und auf die Definition von molekularen Prädiktoren für das Metastasierungspotenzial dieser Zellen konzentrieren. Neben Anwendungen in der Diagnostik und der Prognosebeurteilung könnten sich daraus direkte Auswirkungen auf die Entwicklung zielgerichteter Therapien ergeben.
Abstract
Despite recent developments in therapy for gastric cancer, the prognosis of this disease remains poor in advanced stages. In many cases even curatively treated patients without any residual tumour develop metachronous metastases. As in other solid tumours, adjuvant therapies can reduce the metastatic risk, which implies that some of these patients harbour isolated tumour cells or micrometastases (minimal residual disease, MRD) that are undetectable by radiological imaging and conventional histopathology but can still be the cause of tumour recurrence. Therefore, reliable methods for diagnosing MRD would be desirable for individually tailoring therapy for these patients. Unfortunately, testing methods for MRD and interpretation of their results are not standardised and studies published on this topic are difficult to interpret due to methodological differences and small sample sizes. As of now, testing for MRD has not become relevant in clinical routine for any of the anatomic compartments lymph nodes, peritoneal lavage fluid, peripheral blood, and bone marrow in the Western hemisphere. Most reliable data on MRD in gastric cancer patients have been reported for peritoneal lavage fluid. In some centres in Japan, this test is routinely being used for making therapeutic decisions, e. g., on the use of intraperitoneal chemotherapy. MRD in resected lymph nodes will be further evaluated in the context of the sentinel lymph node concept and possibly be employed for designing individualised therapy for patients in early disease stages who are not routinely candidates for multimodal treatment. As for tumour cells in peripheral blood and in bone marrow, studies suggest that these cells are only able to form metastases in the presence of certain molecular factors. Therefore, rather than simply confirming the existence of isolated tumour cells in blood or bone marrow, future studies should concentrate on defining their molecular characteristics and the conditions required for their metastatic potential. This may gain relevance in diagnostics and prognostic evaluation of individual patients as well as in the development of targeted therapies directly interfering with the metastatic process.
Schlüsselwörter
minimale Resterkrankung - Magenkarzinom - Mikrometastasen - isolierte Tumorzellen
Key words
minimal residual disease - gastric carcinoma - micrometastasis - isolated tumor cells
Literatur
- 1
Cunningham D, Allum W H, Stenning S P et al.
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
N Engl J Med.
2006;
355
11-20
MissingFormLabel
- 2 Boige V, Pignon J, Saint-Aubert B et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin
(P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC
ACCORD07-FFCD 9703 trial. J Clin Oncol, ASCO Annual Meeting Proceedings Part I. Vol. 25, No. 18S (June 20 Supplement), 2007: 4510
MissingFormLabel
- 3
Songun I, Putter H, Kranenbarg E M et al.
Surgical treatment of gastric cancer: 15-year follow-up results of the randomised
nationwide Dutch D 1D2 trial.
Lancet Oncol.
2010;
11
439-449
MissingFormLabel
- 4
Yuasa N, Nimura Y.
Survival after surgical treatment of early gastric cancer, surgical techniques, and
long-term survival.
Langenbecks Arch Surg.
2005;
390
286-293
MissingFormLabel
- 5
Marrelli D, Roviello F, Manzoni G de et al.
Different patterns of recurrence in gastric cancer depending on Lauren’s histological
type: longitudinal study.
World J Surg.
2002;
26
1160-1165
MissingFormLabel
- 6
Knebel Doeberitz von M, Koch M, Weitz J et al.
Diagnosis and significance of minimal residual disease in patients with colorectal
carcinoma.
Zentralbl Chir.
2000;
125 (Suppl 1)
15-19
MissingFormLabel
- 7
Bonadonna G, Gasparini M, Rossi A.
Adjuvant therapies of postsurgical minimal residual disease.
Recent Results Cancer Res.
1980;
74
8-25
MissingFormLabel
- 8
Piñiero A, Giménez J, Vidal-Sicart S et al.
Selective sentinel lymph node biopsy and primary systemic therapy in breast cancer.
Tumori.
2010;
96
17-23
MissingFormLabel
- 9
Maughan K L, Lutterbie M A, Ham P S.
Treatment of breast cancer.
Am Fam Physician.
2010;
81
1339-1346
MissingFormLabel
- 10
Giuliano A E, Dale P S, Turner R R et al.
Improved axillary staging of breast cancer with sentinel lymphadenectomy.
Ann Surg.
1995;
222
394-399
; discussion 399 – 401
MissingFormLabel
- 11
Moroi Y.
Significance of sentinel lymph node biopsy in malignant melanoma: overview of international
data.
Int J Clin Oncol.
2009;
14
485-489
MissingFormLabel
- 12
Gretschel S, Bembenek A, Schulze T et al.
Minimal residual tumor in gastrointestinal carcinoma. Relevance to prognosis and oncologic
surgical consequences.
Chirurg.
2006;
77
1104-1117
MissingFormLabel
- 13
Nicastri D G, Doucette J T, Godfrey T E et al.
Is occult lymph node disease in colorectal cancer patients clinically significant?
A review of the relevant literature.
J Mol Diagn.
2007;
9
563-571
MissingFormLabel
- 14 Edge S B, Byrd D R, Compton C C et al. AJCC Cancer Staging Manual. Springer-Verlag. Berlin; 2010
MissingFormLabel
- 15
Jiang W G, Puntis M C, Hallett M B.
Molecular and cellular basis of cancer invasion and metastasis: implications for treatment.
Br J Surg.
1994;
81
1576-1590
MissingFormLabel
- 16
Hermanek P.
Disseminated tumor cells versus micrometastasis: definitions and problems.
Anticancer Res.
1999;
19
2771-2774
MissingFormLabel
- 17
Hermanek P, Hutter R V, Sobin L H et al.
International Union Against Cancer. Classification of isolated tumor cells and micrometastasis.
Cancer.
1999;
86
2668-2673
MissingFormLabel
- 18
Galus R, Wlodarski K.
Cytokeratin detection as a diagnostic tool in oncology.
Pol Merkur Lekarski (Polski merkuriusz lekarski: organ Polskiego Towarzystwa Lekarskiego).
2007;
23
209-211
MissingFormLabel
- 19
Pantel K, Knebel Doeberitz von M.
Detection and clinical relevance of micrometastatic cancer cells.
Curr Opin Oncol.
2000;
12
95-101
MissingFormLabel
- 20
Pantel K, Schlimok G, Angstwurm M et al.
Methodological analysis of immunocytochemical screening for disseminated epithelial
tumor cells in bone marrow.
J Hematother.
1994;
3
165-173
MissingFormLabel
- 21
Winter M J, Nagtegaal I D, Krieken J HJM et al.
The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a
tool in surgical pathology.
Am J Pathol.
2003;
163
2139-2148
MissingFormLabel
- 22
Bauer K D, La Torre-Bueno van J, Diel de I J et al.
Reliable and sensitive analysis of occult bone marrow metastases using automated cellular
imaging.
Clin Cancer Res.
2000;
6
3552-3559
MissingFormLabel
- 23
Zach O, Lutz D.
Tumor cell detection in peripheral blood and bone marrow.
Curr Opin Oncol.
2006;
18
48-56
MissingFormLabel
- 24
Paterlini-Brechot P, Benali N L.
Circulating tumor cells (CTC) detection: clinical impact and future directions.
Cancer Lett.
2007;
253
180-204
MissingFormLabel
- 25
Pinzani P, Salvadori B, Simi L et al.
Isolation by size of epithelial tumor cells in peripheral blood of patients with breast
cancer: correlation with real-time reverse transcriptase-polymerase chain reaction
results and feasibility of molecular analysis by laser microdissection.
Hum Pathol.
2006;
37
711-718
MissingFormLabel
- 26
Wong N S, Kahn H J, Zhang L et al.
Prognostic significance of circulating tumour cells enumerated after filtration enrichment
in early and metastatic breast cancer patients.
Breast Cancer Res Treat.
2006;
99
63-69
MissingFormLabel
- 27
Allard W J, Matera J, Miller M C et al.
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy
subjects or patients with nonmalignant diseases.
Clin Cancer Res.
2004;
10
6897-6904
MissingFormLabel
- 28
Lee M S, Chang K S, Cabanillas F et al.
Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification.
Science.
1987;
237
175-178
MissingFormLabel
- 29
Gribben J G, Freedman A S, Neuberg D et al.
Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation
for B-cell lymphoma.
N Engl J Med.
1991;
325
1525-1533
MissingFormLabel
- 30
Roth M S, Antin J H, Ash R et al.
Prognostic significance of Philadelphia chromosome-positive cells detected by the
polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous
leukemia.
Blood.
1992;
79
276-282
MissingFormLabel
- 31
Datta Y H, Adams P T, Drobyski W R et al.
Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase
chain reaction.
J Clin Oncol.
1994;
12
475-482
MissingFormLabel
- 32
Hibi K, Robinson C R, Booker S et al.
Molecular detection of genetic alterations in the serum of colorectal cancer patients.
Cancer Res.
1998;
58
1405-1407
MissingFormLabel
- 33
Hsieh J, Lin S, Chang M et al.
APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic
features and postoperative surveillance.
Am Surg.
2005;
71
336-343
MissingFormLabel
- 34
Kobayashi Y, Yoshinouchi M, Tianqi G et al.
Presence of human papilloma virus DNA in pelvic lymph nodes can predict unexpected
recurrence of cervical cancer in patients with histologically negative lymph nodes.
Clin Cancer Res.
1998;
4
979-983
MissingFormLabel
- 35
Müller P, Schlimok G.
Bone marrow „micrometastases” of epithelial tumors: detection and clinical relevance.
J Cancer Res Clin Oncol.
2000;
126
607-618
MissingFormLabel
- 36
Ghossein R A, Bhattacharya S, Rosai J.
Molecular detection of micrometastases and circulating tumor cells in solid tumors.
Clin Cancer Res.
1999;
5
1950-1960
MissingFormLabel
- 37
Mitelman F, Johansson B, Mertens F.
The impact of translocations and gene fusions on cancer causation.
Nat Rev Cancer.
2007;
7
233-245
MissingFormLabel
- 38
Willeke F, Ridder R, Mechtersheimer G et al.
Analysis of FUS-CHOP fusion transcripts in different types of soft tissue liposarcoma
and their diagnostic implications.
Clin Cancer Res.
1998;
4
1779-1784
MissingFormLabel
- 39
Khair G, Monson J RT, Greenman J.
Epithelial molecular markers in the peripheral blood of patients with colorectal cancer.
Dis Colon Rectum.
2007;
50
1188-1203
MissingFormLabel
- 40
Castells A, Boix L, Bessa X et al.
Detection of colonic cells in peripheral blood of colorectal cancer patients by means
of reverse transcriptase and polymerase chain reaction.
Br J Cancer.
1998;
78
1368-1372
MissingFormLabel
- 41
Kim J J, Song K Y, Hur H et al.
Lymph node micrometastasis in node negative early gastric cancer.
Eur J Surg Oncol.
2009;
35
409-414
MissingFormLabel
- 42
Kim J, Park J, Jung C et al.
The significances of lymph node micrometastasis and its correlation with E-cadherin
expression in pT1-T3N0 gastric adenocarcinoma.
J Surg Oncol.
2008;
97
125-130
MissingFormLabel
- 43
Yun H Y, Bandou E, Kawamura T et al.
Influence of micrometastasis on N stage in gastric cancer and clinical application.
J Exp Clin Cancer Res.
2005;
24
531-539
MissingFormLabel
- 44
Sonoda H, Yamamoto K, Kushima R et al.
Detection of lymph node micrometastasis in pN0 early gastric cancer: efficacy of duplex
RT-PCR with MUC2 and TFF1 in mucosal cancer.
Oncol Rep.
2006;
16
411-416
MissingFormLabel
- 45
Yonemura Y, Endo Y, Hayashi I et al.
Proliferative activity of micrometastases in the lymph nodes of patients with gastric
cancer.
Br J Surg.
2007;
94
731-736
MissingFormLabel
- 46
Fukagawa T, Sasako M, Shimoda T et al.
The prognostic impact of isolated tumor cells in lymph nodes of T 2N0 gastric cancer:
comparison of American and Japanese gastric cancer patients.
Ann Surg Oncol.
2009;
16
609-613
MissingFormLabel
- 47
Yanagita S, Natsugoe S, Uenosono Y et al.
Sentinel node micrometastases have high proliferative potential in gastric cancer.
J Surg Res.
2008;
145
238-243
MissingFormLabel
- 48
Arigami T, Natsugoe S, Uenosono Y et al.
Evaluation of sentinel node concept in gastric cancer based on lymph node micrometastasis
determined by reverse transcription-polymerase chain reaction.
Ann Surg.
2006;
243
341-347
MissingFormLabel
- 49
Uenosono Y, Natsugoe S, Ehi K et al.
Detection of sentinel nodes and micrometastases using radioisotope navigation and
immunohistochemistry in patients with gastric cancer.
Br J Surg.
2005;
92
886-889
MissingFormLabel
- 50
Fujiwara Y, Doki Y, Taniguchi H et al.
Genetic detection of free cancer cells in the peritoneal cavity of the patient with
gastric cancer: present status and future perspectives.
Gastric Cancer.
2007;
10
197-204
MissingFormLabel
- 51
Bando E, Yonemura Y, Takeshita Y et al.
Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma.
Am J Surg.
1999;
178
256-262
MissingFormLabel
- 52
Rosenberg R, Nekarda H, Bauer P et al.
Free peritoneal tumour cells are an independent prognostic factor in curatively resected
stage IB gastric carcinoma.
Br J Surg.
2006;
93
325-331
MissingFormLabel
- 53
Bonenkamp J J, Songun I, Hermans J et al.
Prognostic value of positive cytology findings from abdominal washings in patients
with gastric cancer.
Br J Surg.
1996;
83
672-674
MissingFormLabel
- 54
Bentrem D, Wilton A, Mazumdar M et al.
The value of peritoneal cytology as a preoperative predictor in patients with gastric
carcinoma undergoing a curative resection.
Ann Surg Oncol.
2005;
12
347-353
MissingFormLabel
- 55
Ribeiro U, Safatle-Ribeiro A V, Zilberstein B et al.
Does the intraoperative peritoneal lavage cytology add prognostic information in patients
with potentially curative gastric resection?.
J Gastrointest Surg.
2006;
10
170-176, discussion 176 – 177
MissingFormLabel
- 56
Ishii T, Fujiwara Y, Ohnaka S et al.
Rapid genetic diagnosis with the transcription-reverse transcription concerted reaction
system for cancer micrometastasis.
Ann Surg Oncol.
2004;
11
778-785
MissingFormLabel
- 57
Kodera Y, Nakanishi H, Ito S et al.
Prognostic significance of intraperitoneal cancer cells in gastric carcinoma: detection
of cytokeratin 20 mRNA in peritoneal washes, in addition to detection of carcinoembryonic
antigen.
Gastric Cancer.
2005;
8
142-148
MissingFormLabel
- 58
Bessa X, Piñol V, Castellví-Bel S et al.
Prognostic value of postoperative detection of blood circulating tumor cells in patients
with colorectal cancer operated on for cure.
Ann Surg.
2003;
237
368-375
MissingFormLabel
- 59
Ikeguchi M, Kaibara N.
Detection of circulating cancer cells after a gastrectomy for gastric cancer.
Surg Today.
2005;
35
436-441
MissingFormLabel
- 60
Smith H W, Marshall C J.
Regulation of cell signalling by uPAR.
Nat Rev Mol Cell Biol.
2010;
11
23-36
MissingFormLabel
- 61
Kita Y, Fukagawa T, Mimori K et al.
Expression of uPAR mRNA in peripheral blood is a favourite marker for metastasis in
gastric cancer cases.
Br J Cancer.
2009;
100
153-159
MissingFormLabel
- 62
Kaplan R N, Riba R D, Zacharoulis S et al.
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic
niche.
Nature.
2005;
438
820-827
MissingFormLabel
- 63
Mimori K, Fukagawa T, Kosaka Y et al.
Hematogenous metastasis in gastric cancer requires isolated tumor cells and expression
of vascular endothelial growth factor receptor-1.
Clin Cancer Res.
2008;
14
2609-2616
MissingFormLabel
- 64
Mimori K, Fukagawa T, Kosaka Y et al.
A large-scale study of MT 1-MMP as a marker for isolated tumor cells in peripheral
blood and bone marrow in gastric cancer cases.
Ann Surg Oncol.
2008;
15
2934-2942
MissingFormLabel
- 65
Hildenbrand R, Allgayer H, Marx A et al.
Modulators of the urokinase-type plasminogen activation system for cancer.
Expert Opin Investig Drugs.
2010;
19
641-652
MissingFormLabel
- 66
Mekkawy A H, Morris D L, Pourgholami M H.
Urokinase plasminogen activator system as a potential target for cancer therapy.
Future Oncol.
2009;
5
1487-1499
MissingFormLabel
- 67
Lindemann F, Schlimok G, Dirschedl P et al.
Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal
cancer patients.
Lancet.
1992;
340
685-689
MissingFormLabel
- 68
Jauch K W, Heiss M M, Gruetzner U et al.
Prognostic significance of bone marrow micrometastases in patients with gastric cancer.
J Clin Oncol.
1996;
14
1810-1817
MissingFormLabel
- 69
Thorban S, Roder J D, Nekarda H et al.
Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients
with esophageal carcinoma.
J Natl Cancer Inst.
1996;
88
1222-1227
MissingFormLabel
- 70
Schlimok G, Funke I, Pantel K et al.
Micrometastatic tumour cells in bone marrow of patients with gastric cancer: methodological
aspects of detection and prognostic significance.
Eur J Cancer.
1991;
27
1461-1465
MissingFormLabel
- 71
Putz E, Witter K, Offner S et al.
Phenotypic characteristics of cell lines derived from disseminated cancer cells in
bone marrow of patients with solid epithelial tumors: establishment of working models
for human micrometastases.
Cancer Res.
1999;
59
241-248
MissingFormLabel
- 72
Wang G, Li Y, Yu Y et al.
Detection of disseminated tumor cells in bone marrow of gastric cancer using magnetic
activated cell sorting and fluorescent activated cell sorting.
J Gastroenterol Hepatol.
2009;
24
299-306
MissingFormLabel
- 73
Wang G, Wang S, Li Y et al.
Detecting bone marrow micrometastasis of gastric cancer by magnetic activated cell
sorting combined with fluorescent activated cell sorting.
Ai Zheng.
2005;
24
605-610
MissingFormLabel
- 74
Iwatsuki M, Mimori K, Fukagawa T et al.
The Clinical Significance of Vimentin-Expressing Gastric Cancer Cells in Bone Marrow.
Ann Surg Oncol.
2010;
17 (9)
2526-2533
MissingFormLabel
- 75
Iwatsuki M, Fukagawa T, Mimori K et al.
Bone marrow and peripheral blood expression of ID 1 in human gastric carcinoma patients
is a bona fide indicator of lymph node and peritoneal metastasis.
Br J Cancer.
2009;
100
1937-1942
MissingFormLabel
- 76
Kolodziejczyk P, Pituch-Noworolska A, Drabik G et al.
The effects of preoperative chemotherapy on isolated tumour cells in the blood and
bone marrow of gastric cancer patients.
Br J Cancer.
2007;
97
589-592
MissingFormLabel
- 77
Ryan P, McCarthy S, Kelly J et al.
Prevalence of bone marrow micrometastases in esophagogastric cancer patients with
and without neoadjuvant chemoradiotherapy.
J Surg Res.
2004;
117
121-126
MissingFormLabel
- 78
Arigami T, Natsugoe S, Uenosono Y et al.
CCR7 and CXCR4 expression predicts lymph node status including micrometastasis in
gastric cancer.
Int J Oncol.
2009;
35
19-24
MissingFormLabel
- 79
Ishii K, Kinami S, Funaki K et al.
Detection of sentinel and non-sentinel lymph node micrometastases by complete serial
sectioning and immunohistochemical analysis for gastric cancer.
J Exp Clin Cancer Res.
2008;
27
7-13
MissingFormLabel
- 80
Morita D, Tsuda H, Ichikura T et al.
Analysis of sentinel node involvement in gastric cancer.
Clin Gastroenterol Hepatol.
2007;
5
1046-1052
MissingFormLabel
- 81
Miyake K, Seshimo A, Kameoka S.
Assessment of lymph node micrometastasis in early gastric cancer in relation to sentinel
nodes.
Gastric Cancer.
2006;
9
197-202
MissingFormLabel
- 82
Wu Z, Zhan W, Li J et al.
[Value of lymph node micrometastasis detected by RT-PCR assay in determining the stage
of gastric carcinoma].
Zhonghua Wei Chang Wai Ke Za Zhi.
2006;
9
217-220
MissingFormLabel
- 83
Katsuragi K, Yashiro M, Sawada T et al.
Prognostic impact of PCR-based identification of isolated tumour cells in the peritoneal
lavage fluid of gastric cancer patients who underwent a curative R 0 resection.
Br J Cancer.
2007;
97
550-556
MissingFormLabel
- 84
Da M X, Wu X T, Guo T K et al.
Clinical significance of telomerase activity in peritoneal lavage fluid from patients
with gastric cancer and its relationship with cellular proliferation.
World J Gastroenterol.
2007;
13
3122-3127
MissingFormLabel
- 85
Kodera Y, Nakanishi H, Ito S et al.
Prognostic significance of intraperitoneal cancer cells in gastric carcinoma: analysis
of real time reverse transcriptase-polymerase chain reaction after 5 years of followup.
J Am Coll Surg.
2006;
202
231-236
MissingFormLabel
- 86
Wang Z, Zhang X, Xu H et al.
Detection of peritoneal micrometastasis by reverse transcriptase-polymerase chain
reaction for heparanase mRNA and cytology in peritoneal wash samples.
J Surg Oncol.
2005;
90
59-65
MissingFormLabel
- 87
Wang Z, Xu H, Jiang L et al.
Expression of survivin mRNA in peritoneal lavage fluid from patients with gastric
carcinoma.
Chin Med J.
2004;
117
1210-1217
MissingFormLabel
- 88
Koga T, Tokunaga E, Sumiyoshi Y et al.
Detection of circulating gastric cancer cells in peripheral blood using real time
quantitative RT-PCR.
Hepatogastroenterology.
2008;
55
1131-1135
MissingFormLabel
- 89
Wu C H, Lin S R, Hsieh J S et al.
Molecular detection of disseminated tumor cells in the peripheral blood of patients
with gastric cancer: evaluation of their prognostic significance.
Dis Markers.
2006;
22
103-109
MissingFormLabel
- 90
Chen X, Chen G, Wang Z et al.
Detection of micrometastasis of gastric carcinoma in peripheral blood circulation.
World J Gastroenterol.
2004;
10
804-808
MissingFormLabel
- 91
Zhang X, Fan P, Yang H et al.
Significance of detecting disseminated tumor cells in peripheral blood of gastric
and colorectal cancer patients.
Zhonghua Zhong Liu Za Zhi.
2003;
25
66-69
MissingFormLabel
- 92
Oki E, Kakeji Y, Baba H et al.
Clinical significance of cytokeratin positive cells in bone marrow of gastric cancer
patients.
J Cancer Res Clin Oncol.
2007;
133
995-1000
MissingFormLabel
- 93
Gretschel S, Schick C, Schneider U et al.
Prognostic value of cytokeratin-positive bone marrow cells of gastric cancer patients.
Ann Surg Oncol.
2007;
14
373-380
MissingFormLabel
- 94
Fujita Y, Terashima M, Hoshino Y et al.
Detection of cancer cells disseminated in bone marrow using real-time quantitative
RT-PCR of CEA, CK 19, and CK 20 mRNA in patients with gastric cancer.
Gastric Cancer.
2006;
9
308-314
MissingFormLabel
- 95
Matsunami K, Nakamura T, Oguma H et al.
Detection of bone marrow micrometastasis in gastric cancer patients by immunomagnetic
separation.
Ann Surg Oncol.
2003;
10
171-175
MissingFormLabel
Dr. Benjamin Garlipp
Klinik für Allgemein-, Viszeral- und Gefäßchirurgie, Universitätsklinikum Magdeburg
Leipziger Straße 44
39120 Magdeburg
Telefon: ++ 49/3 91/6 71 55 00
Fax: ++ 49/3 91/6 71 55 70
eMail: benjamin.garlipp@med.ovgu.de